Source: The Hill Politics
Summary
An FDA panel has unanimously approved Moderna’s mFlusiva flu shot for adults aged 50 and older, determining its benefits outweigh risks. This decision marks a significant advancement in flu vaccination options, particularly for vulnerable populations.
Why It Matters
The approval of Moderna’s flu shot could enhance protection against seasonal influenza, potentially reducing hospitalizations and healthcare costs for seniors. As flu strains evolve, effective vaccines are crucial in safeguarding public health, especially for older adults who are at higher risk.




